Buy Bufotenin (dimethylserotonin) Cas-487-93-4

Buy Bufotenin (dimethylserotonin) Cas-487-93-4

Bufotenin, also known as dimethylserotonin or as 5-hydroxy-N,N-dimethyltryptamine (5-HO-DMT), is a serotonergic psychedelic of the tryptamine family. It is a derivative of the psychedelic dimethyltryptamine (DMT) and of the neurotransmitter serotonin (5-hydroxytryptamine; 5-HT). The compound is an alkaloid found in some species of mushrooms, plants, and toads. It is also found naturally in the human body in small amounts.^[7][8][9] Bufotenin, for instance derived from the trees Anadenanthera colubrina and Anadenanthera peregrina, has a long history of entheogenic use as a snuff in South America.^{[1][5][10][11]}

The name bufotenin originates from the toad genus Bufo, which includes several species of psychoactive toads, most notably Incilius alvarius (formerly Bufo alvarius), that secrete bufotoxins from their parotoid glands.^[12] However, Bufo and related species like Incilius alvarius contain only trace amounts of bufotenin, with their major active component instead being 5-MeO-DMT. In addition to DMT and serotonin, bufotenin is similar in chemical structure to other psychedelics such as 5-MeO-DMT and psilocin (4-HO-DMT). These compounds also occur in some of the same fungus, plant, and animal species as bufotenin.

Bufotenin acts as a potent and non-selective serotonin receptor agonist, including of the serotonin 5-HT_1A, 5-HT_2A, 5-HT_2C, and 5-HT₃ receptors, among others.^{[13][6][8][14]} It also acts as a potent and specific serotonin releasing agent.^[14] The compound is more hydrophilic than other related tryptamines and consequently is more peripherally selective.^[13][15] In relation to this, bufotenin has been associated with prominent peripheral serotonergic side effects, such as cardiovascular changes.^[13][8][16] The cardiovascular effects of bufotenin can be powerful and potentially dangerous.^[17]

For many decades and even into the present, bufotenin has been considered by many experts, such as David E. Nichols, to be either inactive or only weakly active as a psychedelic in humans and to produce robust toxic effects.^{[15][2][13][3]} Alexander Shulgin was also uncertain whether bufotenin was an active psychedelic.^[16][18][5] However, Jonathan Ott found in 2001 via self-experimentation that bufotenin is in fact a potent psychedelic and does not necessarily produce serious adverse effects.^[3][5][2][1] Hamilton Morris has further supported these findings with his own self-experimentation, although bufotenin was reported to be strongly nauseating for himself and many others.^[10][5] According to Morris, the psychedelic effects of bufotenin are like a cross between those of DMT and 5-MeO-DMT.^[10][5] Morris has stated that bufotenin may in fact be the psychedelic with the longest history of human entheogenic use.^[10][5] Bufotenin has also been encountered as a recreational drug in forensic samples, for instance in New York City.^[19]

This section relies excessively on references to primary sources. Please improve this section by adding secondary or tertiary sources. (May 2019) (Learn how and when to remove this message)

In 1955, Fabing and Hawkins administered bufotenin intravenously at doses of up to 16 mg to prison inmates at Ohio State Penitentiary.^[4] A toxic effect causing purpling of the face was seen in these tests.

A subject given 1 mg reported “a tight feeling in the chest” and prickling “as if he had been jabbed by needles.” This was accompanied by a “fleeting sensation of pain in both thighs and a mild nausea.”^[4]

Another subject given 2 mg reported “tightness in his throat.” He had tightness in the stomach, tingling in pretibial areas, and developed a purplish hue in the face indicating blood circulation problems. He vomited after 3 minutes.^[4]

Another subject given 4 mg complained of “chest oppression” and that “a load is pressing down from above and my body feels heavy.” The subject also reported “numbness of the entire body” and “a pleasant Martini feeling-my body is taking charge of my mind.” The subject reported he saw red spots passing before his eyes and red-purple spots on the floor, and the floor seemed very close to his face. Within 2 minutes these visual effects were gone, and replaced by a yellow haze, as if he were looking through a lens filter.^[4]

Fabing and Hawkins commented that bufotenin’s psychedelic effects were “reminiscent of [LSD] and mescaline but develop and disappear more quickly, indicating rapid central action and rapid degradation of the drug”.^[4]

In 1956, Harris Isbell at the Public Health Service Hospital in Lexington, Kentucky, experimented with bufotenin as a snuff made from Anadenanthera peregrina.^[20] He reported “no subjective or objective effects were observed after spraying with as much as 40 mg bufotenine”; however, subjects who received 10–12 mg by intramuscular injection reported “elements of visual hallucinations consisting of a play of colors, lights, and patterns.”^[21][22][20]

Turner and Merlis (1959)^[22] experimented with intravenous administration of bufotenin (as the water-soluble creatinine sulfate salt) to schizophrenics at a New York state hospital. They reported that when one subject received 10 mg during a 50-second interval, “the peripheral nervous system effects were extreme: at 17 seconds, flushing of the face, at 22 seconds, maximal inhalation, followed by maximal hyperventilation for about 2 minutes, during which the patient was unresponsive to stimuli; her face was plum-colored.” Finally, Turner and Merlis reported:

on one occasion, which essentially terminated our study, a patient who received 40 mg intramuscularly, suddenly developed an extremely rapid heart rate; no pulse could be obtained; no blood pressure measured. There seemed to have been an onset of auricular fibrillation . . . extreme cyanosis developed. Massage over the heart was vigorously executed and the pulse returned to normal . . . shortly thereafter the patient, still cyanotic, sat up saying: “Take that away. I don’t like them.”

After pushing doses to the morally admissible limit without producing visuals, Turner and Merlis conservatively concluded: “We must reject bufotenine . . . as capable of producing the acute phase of Cohoba intoxication.”^[21]

Albert Hofmann tried bufotenin orally at doses of up to 50 mg but experienced no psychoactive effects.^[23][1]

A 1985 study by McLeod and Sitaram in humans reported that bufotenin administered intranasally at a dose of 1–16 mg had no effect, other than intense local irritation. When given intravenously at low doses (2–4 mg), bufotenin oxalate caused anxiety but no other effects; however, a dose of 8 mg resulted in profound emotional and perceptual changes, involving extreme anxiety, a sense of imminent death, and visual disturbance associated with color reversal and distortion, and intense flushing of the cheeks and forehead